Matritech assesses breast cancer screening test:
This article was originally published in Clinica
Matritech has begun a multicentre clinical trial in the US to investigate whether its NMP66 blood test for breast cancer has potential as a screening tool for the disease. Researchers will assess how well the test detects breast cancer, differentiates between benign and malignant lesions and identifies patients with normal mammograms, says the Newton, Massachusetts company, which has begun recruiting patients for the study. The trial will be conducted at six centres and will enrol around 1,000 patients.